Literature DB >> 21209108

Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets.

Judith M A van den Brand1, Joost H C M Kreijtz, Rogier Bodewes, Koert J Stittelaar, Geert van Amerongen, Thijs Kuiken, James Simon, Ron A M Fouchier, Giuseppe Del Giudice, Rino Rappuoli, Guus F Rimmelzwaan, Albert D M E Osterhaus.   

Abstract

Serum antibodies induced by seasonal influenza or seasonal influenza vaccination exhibit limited or no cross-reactivity against the 2009 pandemic swine-origin influenza virus of the H1N1 subtype (pH1N1). Ferrets immunized once or twice with MF59-adjuvanted seasonal influenza vaccine exhibited significantly reduced lung virus titers but no substantial clinical protection against pH1N1-associated disease. However, priming with MF59-adjuvanted seasonal influenza vaccine significantly increased the efficacy of a pandemic MF59-adjuvanted influenza vaccine against pH1N1 challenge. Elucidating the mechanism involved in this priming principle will contribute to our understanding of vaccine- and infection-induced correlates of protection. Furthermore, a practical consequence of these findings is that during an emerging pandemic, the implementation of a priming strategy with an available adjuvanted seasonal vaccine to precede the eventual pandemic vaccination campaign may be useful and life-saving.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21209108      PMCID: PMC3067945          DOI: 10.1128/JVI.01939-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.

Authors:  Filippo Ansaldi; Sabrina Bacilieri; Paolo Durando; Laura Sticchi; Laura Valle; Emanuele Montomoli; Giancarlo Icardi; Roberto Gasparini; Pietro Crovari
Journal:  Vaccine       Date:  2008-02-01       Impact factor: 3.641

Review 2.  Influenza vaccine: the challenge of antigenic drift.

Authors:  F Carrat; A Flahault
Journal:  Vaccine       Date:  2007-08-03       Impact factor: 3.641

3.  Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Authors:  Grazia Galli; Kathy Hancock; Katja Hoschler; Joshua DeVos; Michaela Praus; Monia Bardelli; Carmine Malzone; Flora Castellino; Chiara Gentile; Teresa McNally; Giuseppe Del Giudice; Angelika Banzhoff; Volker Brauer; Emanuele Montomoli; Maria Zambon; Jacqueline Katz; Karl Nicholson; Iain Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-27       Impact factor: 11.205

4.  The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines.

Authors:  Kristin L Nichol
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

5.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

6.  Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Authors:  Iain Stephenson; Roberto Bugarini; Karl G Nicholson; Audino Podda; John M Wood; Maria C Zambon; Jacqueline M Katz
Journal:  J Infect Dis       Date:  2005-03-14       Impact factor: 5.226

7.  Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands.

Authors:  G F Rimmelzwaan; J C de Jong; T M Bestebroer; A M van Loon; E C Claas; R A Fouchier; A D Osterhaus
Journal:  Virology       Date:  2001-04-10       Impact factor: 3.616

Review 8.  MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

Authors:  D T O'Hagan; A Wack; A Podda
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

9.  Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro.

Authors:  G F Rimmelzwaan; M Baars; E C Claas; A D Osterhaus
Journal:  J Virol Methods       Date:  1998-09       Impact factor: 2.014

10.  Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement.

Authors:  A L Frank; J Puck; B J Hughes; T R Cate
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

View more
  24 in total

1.  Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Authors:  Kar Muthumani; Seleeke Flingai; Megan Wise; Colleen Tingey; Kenneth E Ugen; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2013-09-17       Impact factor: 3.452

2.  Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Authors:  Michela Brazzoli; Diletta Magini; Alessandra Bonci; Scilla Buccato; Cinzia Giovani; Roland Kratzer; Vanessa Zurli; Simona Mangiavacchi; Daniele Casini; Luis M Brito; Ennio De Gregorio; Peter W Mason; Jeffrey B Ulmer; Andrew J Geall; Sylvie Bertholet
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

3.  Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume.

Authors:  Ian N Moore; Elaine W Lamirande; Myeisha Paskel; Danielle Donahue; Heather Kenney; Jing Qin; Kanta Subbarao
Journal:  J Virol       Date:  2014-09-03       Impact factor: 5.103

4.  Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.

Authors:  Teena Mohan; Jongrok Kim; Zachary Berman; Shelly Wang; Richard W Compans; Bao-Zhong Wang
Journal:  J Control Release       Date:  2016-05-10       Impact factor: 9.776

5.  Influenza A Virus Reassortment Is Limited by Anatomical Compartmentalization following Coinfection via Distinct Routes.

Authors:  Mathilde Richard; Sander Herfst; Hui Tao; Nathan T Jacobs; Anice C Lowen
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

6.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

7.  A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.

Authors:  Joost H C M Kreijtz; Lidewij C M Wiersma; Heidi L M De Gruyter; Stella E Vogelzang-van Trierum; Geert van Amerongen; Koert J Stittelaar; Ron A M Fouchier; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  J Infect Dis       Date:  2014-09-22       Impact factor: 5.226

8.  Pulmonary pathology of pandemic influenza A/H1N1 virus (2009)-infected ferrets upon longitudinal evaluation by computed tomography.

Authors:  Edwin J B Veldhuis Kroeze; Geert van Amerongen; Marcel L Dijkshoorn; James H Simon; Leon de Waal; Ieneke J C Hartmann; Gabriel P Krestin; Thijs Kuiken; Albert D M E Osterhaus; Koert J Stittelaar
Journal:  J Gen Virol       Date:  2011-05-04       Impact factor: 3.891

9.  Towards universal influenza vaccines?

Authors:  Ab Osterhaus; Ron Fouchier; Guus Rimmelzwaan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

10.  Comparison of temporal and spatial dynamics of seasonal H3N2, pandemic H1N1 and highly pathogenic avian influenza H5N1 virus infections in ferrets.

Authors:  Judith M A van den Brand; Koert J Stittelaar; Geert van Amerongen; Leslie Reperant; Leon de Waal; Albert D M E Osterhaus; Thijs Kuiken
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.